Bausch Health Companies stock holds steady as analysts stick to Reduce rating

Published on 09/19/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bausch Health Companies stock traded around USD 5.63 on September 18, 2026, while brokerages kept an average Reduce recommendation with a USD 8.00 price target. Recent trading shows limited upside but highlights cautious sentiment toward the company’s turnaround efforts.

BHC, CA0717341071, Illustration mit AI erstellt.

Bausch Health Companies Inc. (ISIN CA0717341071) stock was quoted at around USD 5.63 on the New York Stock Exchange on September 18, 2026, reflecting only a modest move despite a cautious analyst stance and an average 12-month price target of USD 8.00 that implies upside from current levels.

Analysts maintain Reduce stance with modest upside

According to MarketBeat on September 18, 2026, seven brokerages currently cover Bausch Health Companies, giving the shares an average recommendation of Reduce, with one sell rating and six hold ratings in place.

The same analyst overview cites an average 12-month price target of USD 8.00, compared with a referenced share price of USD 5.63, indicating potential upside of roughly 42 percent if the stock were to reach the consensus target, even as the overall rating remains cautious.

Share price and recent trading range

In recent trading, Bausch Health shares changed hands at about USD 5.67 on September 18, 2026, with a small intraday gain of 0.27 percent, per data from an Investing.com candlestick overview that lists BHC at USD 5.67 and a change of USD 0.02 for that session.

The same overview shows a day’s range between USD 5.60 and USD 5.73 on September 18, 2026, suggesting that the stock is currently consolidating within a narrow band rather than making a pronounced move in either direction.

Ownership structure and insider activity frame the risk profile

According to the analyst and trading snapshot from MarketBeat, institutional investors own about 78.65 percent of Bausch Health’s shares, while insiders collectively hold around 20.67 percent, pointing to a significant mix of professional and internal ownership.

The same report notes that insider Aimee Lenar sold 36,827 shares in a transaction dated August 19, 2026 at an average price of USD 7.03, for total proceeds of USD 258,893.81, reducing her position by 9.91 percent to 334,853 shares; this sale at a higher price than the mid-September level underlines how the stock has since traded below that insider sale reference.

Sector backdrop adds competitive pressure

Bausch Health operates in the broader healthcare and medical technology space, where body-contouring and aesthetic devices have been highlighted as a growth area; a GlobeNewswire industry note on September 19, 2026 mentions Bausch Health Companies alongside other manufacturers as players in the expanding body-contouring devices segment, underscoring the competitive backdrop for its product portfolio.

Stock valuation perspective for investors

With Bausch Health Companies stock around USD 5.63 to USD 5.67 as of September 18, 2026 on its primary New York Stock Exchange listing, and the analyst consensus price target at USD 8.00 over 12 months, investors face a mix of potential upside and clear caution, as reflected in the Reduce rating and the recent drift of the share price below earlier insider sale levels.